Human papillomavirus quadrivalent (types 6, 11, 16, 18) vaccine, recombinant (Hansenula polymorpha, Jiangsu Recbio Technology)

重组四价人乳头瘤病毒疫苗（汉逊酵母，江苏瑞科生物）

Report date: 2025/12/11 09:50:57

Base Information

Drug NameHuman papillomavirus quadrivalent (types 6, 11, 16, 18) vaccine, recombinant (Hansenula polymorpha, Jiangsu Recbio Technology)

Drug Alias Name重组人乳头瘤病毒6/11/16/18型四价疫苗（汉逊酵母）Novel adjuvanted recombinant HPV quadrivalent vaccine (BFA04)新佐剂重组四价HPV疫苗（BFA04佐剂）REC-604a

ClassificationVaccines > Biological material > Viral vaccineVaccines > Development/production technology > Genetically engineered subunit vaccineVaccines > National Immunization Program > Non-immunization program vaccine(Class II) +[5]

Mechanisms of ActionImmunostimulants

TargetsNot applicable

Therapy Area/IndicationsPapillomavirus Infections

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaPhase 1 Clinical

Originator CompaniesJiangsu Rec-Biotechnology Co Ltd

China Registration ClassN/A

Develop Information

Active CompaniesJiangsu Rec-Biotechnology Co Ltd

Inactive CompaniesN/A

Active IndicationsPapillomavirus Infections

Inactive IndicationsN/A

Other Information

ATC CodeN/A